1 overall survival, respectively, with 5 years
median follow-up time.
2 On follow-up (
median follow-up time 11.9 months, range 8-24), there wa
3 With a
median follow-up time 12 years in S0014, 5- and 10-year
4 After re-DMEK (
median follow-up time 14.5 [42.5] months), mean BCVA imp
5 es did not need surgical or laser treatment (
median follow-up time 15 months).
6 following 4,123 healthy men every 6 months (
median follow-up time,
4.1 years).
7 positive viremic women with HIV coinfection (
median follow-up time,
5.2 years).
8 with follow-up ranging from 1 to 11 visits (
median follow-up time,
5.5 years; range, 1.4-32.7 years,
9 tive cohort study (2009-2019) were included (
median follow-up time,
5.9 y).
10 hnicity (97% vs. 99% European; P = 0.3), and
median follow-up time (
6.5 years vs. 3 years; P = 0.3).
11 ata were available for 290 Native Americans (
median follow-up time:
6.6 years).
12 821), median exposure (3.3 vs 1.8 years) and
median follow-up time (
62 vs 26 months) have increased.
13 NODM was reported in 4.6% (
median follow-up time:
693 days).
14 3 recipients without pretransplant diabetes (
median follow-up time,
713 days).
15 eligible for the primary analysis (mean and
median follow-up times 8.7 and 10 years).
16 (54.3% female; mean age, 61.6 +/- 7.1 years;
median follow-up time,
8.1 years from the baseline colon
17 the basis of 271 occurrences of HF during a
median follow-up time after cohort entry of 17.3 years (
18 The
median follow-up time after cure was 11 months, during w
19 The overall
median follow-up time after diagnosis was 52.7 months fo
20 Median follow-up time after implant placement was 6 year
21 The
median follow-up time after random allocation was 10.3 y
22 The
median follow-up time after randomization was 54 months
23 The
median follow-up time after the first RTX course was 36.
24 With a
median follow-up time among survivors of 7.6 years (rang
25 With a
median follow-up time among survivors of 7.6 years (rang
26 The
median follow-up time and number of visits were 1.7 year
27 The
median follow-up time for all 114 subjects was 26.70 mon
28 Median follow-up time for all evaluable patients was 42
29 patients were excluded in the calculation of
median follow-up time for all patients.
30 At a
median follow-up time for all randomised patients of 12.
31 us as potentially associated with prognosis (
median follow-up time for genotypes: CC = 4 years, CT =
32 Median follow-up time for matched patients was 7.8 years
33 ployees (n = 2,476) was 8,469 years, and the
median follow-up time for participants was 4.0 years.
34 Median follow-up time for patients alive at time of anal
35 Median follow-up time for patients still alive was 8.4 y
36 Median follow-up time for survival analysis was 20.0 mon
37 The
median follow-up time for the 70 patients enrolled was 3
38 Median follow-up time for the cohort was 58 months.
39 Median follow-up time for the HPV group was 11.1 years (
40 The
median follow-up time from diagnosis for all alive patie
41 ow-up visit with an ophthalmologist, and the
median follow-up time from pseudostrabismus diagnosis to
42 Among the 819 survivors, the
median follow-up time from the first biopsy is 6.4 years
43 Median follow-up time from transplantation to end of fol
44 The
median follow-up time in MADIT-II, SCD-HeFT, and the ICD
45 The
median follow-up time in survivors was 4.4 years.
46 months, and median OS has not been reached;
median follow-up time is 10.7 months.
47 SVTs despite 3 ablation procedures during a
median follow-up time of >200 days.
48 During a
median follow-up time of 10.1 years (interquartile range
49 a persistent response to vemurafenib, with a
median follow-up time of 10.5 months (range, 6 to 16 mon
50 Over a
median follow-up time of 10.7 years (56,403 total person
51 During a
median follow-up time of 10.7 years, there were 1,105 co
52 During a
median follow-up time of 10.9 years (interquartile range
53 After a
median follow-up time of 11 months, the median overall s
54 With a
median follow-up time of 12 months and 382 deaths, there
55 During a
median follow-up time of 12.5 years, 13.2% (n = 6596) di
56 After a
median follow-up time of 12.8 y, 23,828 deaths were iden
57 allograft function and proteinuria during a
median follow-up time of 1386 days (range, 332-6254).
58 icipants, 1,496 deaths were recorded after a
median follow-up time of 14 years (1998-2012).
59 The mean age was 66.6 +/- 19.2 years with a
median follow-up time of 147 days.
60 , and high-risk groups, respectively, with a
median follow-up time of 15 months.
61 After a
median follow-up time of 15 y, prostate cancer was diagn
62 During a
median follow-up time of 16 months, 218 events occurred.
63 In the MDCS, over a
median follow-up time of 16.1 years, aortic stenosis dev
64 0 eyes from 13 patients were included with a
median follow-up time of 17 months.
65 s is 90%, and all patients are alive after a
median follow-up time of 17 months.
66 39 patients was 63.0 (range 4-95 years) with
median follow-up time of 170 days.
67 months (95% CI, 17.3 to 26.3 months) after a
median follow-up time of 18 months (range, 0.3 to 67.6 m
68 PFS) and disease-specific mortality during a
median follow-up time of 18 months (range, 4-35 months).
69 During a
median follow-up time of 18 months, 102 (24%) were hospi
70 With a
median follow-up time of 18 months, 55 patients (76%) ha
71 had progressed in 17 patients (5.1%) after a
median follow-up time of 19 months.
72 verall survival has yet to be reached with a
median follow-up time of 19.3 mo (range, 5.8-45.3 mo).
73 induced sustained clinical remission with a
median follow-up time of 2 years.
74 During a
median follow-up time of 2.2 years (range, 0 to 23 years
75 t laparoscopic AGB or RYGB procedures with a
median follow-up time of 2.3 years (maximum, 6 years).
76 Over a
median follow-up time of 2.76 years (interquartile range
77 129; ductal carcinoma in situ,n = 47) over a
median follow-up time of 2.8 years.
78 After a
median follow-up time of 21.9 months (IQR 12.1-31.0) in
79 Seventy-two patients were included with a
median follow-up time of 22 months.
80 -seven eligible patients were accrued with a
median follow-up time of 22.2 months.
81 After a
median follow-up time of 23 months (range, 6.1-54.7 mont
82 values did not differ significantly during a
median follow-up time of 24 months (median intra-patient
83 s is 88%, and all patients are alive after a
median follow-up time of 24 months.
84 After a
median follow-up time of 24.3 years (mean = 25.6 years),
85 With a
median follow-up time of 26 months and 54 progression ev
86 After a
median follow-up time of 26 months, VT recurred in 164 (
87 s underwent a total of 19 procedures, with a
median follow-up time of 26.4 months.
88 Now, with a
median follow-up time of 27 months, median survival time
89 After a
median follow-up time of 27.3 weeks, patients with a pro
90 Over a
median follow-up time of 28 (11-48) months, 18 patients
91 After a
median follow-up time of 29.1 months in KEYNOTE-013 and
92 At a
median follow-up time of 3 years (interquartile range, 2
93 Over a
median follow-up time of 3.01 (interquartile range=1.56-
94 uring subsequent annual surveillance, with a
median follow-up time of 3.1 years (interquartile range,
95 ith T2DM, 20.1% and 7.2% developed DR over a
median follow-up time of 3.2 and 3.1 years, respectively
96 ratio, 1.16; 95% CI, 0.97 to 1.38) during a
median follow-up time of 3.3 years.
97 Results With a
median follow-up time of 3.4 years, the estimated cumula
98 Follow-up was 99.8% with a
median follow-up time of 3.7 years (interquartile range,
99 At a
median follow-up time of 31 months, median PFS was 42 mo
100 With a
median follow-up time of 32 months, the median overall s
101 At a
median follow-up time of 33 months, locoregional or syst
102 mmol/l, 95%CI:0.26-0.74, p = 0.002) after a
median follow-up time of 33(21-36) months.
103 During a
median follow-up time of 35 months (interquartile range,
104 from November 2006 through July 2012, with a
median follow-up time of 35 months in an ambulatory care
105 With a
median follow-up time of 35 months, two (4.8%) of 41 pat
106 Results After a
median follow-up time of 35.7 months, 190 patients had d
107 e partial tumor response are ongoing after a
median follow-up time of 36 months (range, 22 to 43 mont
108 During a
median follow-up time of 37 months, 4-year estimates of
109 ocardiographic follow-up were completed at a
median follow-up time of 37 months.
110 With an updated
median follow-up time of 38.8 months (range, 28.3 to 61.
111 2 controls from 7 European countries after a
median follow-up time of 4.1 years.
112 with a diagnosis of prostate cancer after a
median follow-up time of 4.2 y and 1061 matched controls
113 TTs) and 99.6% in the low-risk group, with a
median follow-up time of 4.2 years.
114 At
median follow-up time of 4.70 years after the second kid
115 us, and cause of death were documented for a
median follow-up time of 4.8 y.
116 During a
median follow-up time of 4.8 years, there were 339 (60%)
117 us, and cause of death were documented for a
median follow-up time of 4.9 y.
118 (1223 surgical and 5978 nonsurgical) with a
median follow-up time of 4.9 years (interquartile range,
119 imary carotid body paraganglioma resections (
median follow-up time of 42 months, range: 1-293).
120 With a
median follow-up time of 43 months, the nonrelapse morta
121 ts were enrolled at eight dose levels with a
median follow-up time of 44.6 months; data cutoff was Ja
122 nts were obtained at recruitment and after a
median follow-up time of 5 y.
123 During a
median follow-up time of 5 years, 124 CVD events occurre
124 mission and no evidence of recurrence over a
median follow-up time of 5 years.
125 ars of follow-up after transplantation and a
median follow-up time of 5.1 years (interquartile range,
126 During a
median follow-up time of 5.1 years (IQR 2.6-7.5), we rec
127 l of 7542 recipients were followed up over a
median follow-up time of 5.3 years (interquartile range
128 0.64 years of age had available data after a
median follow-up time of 5.33 years in the GnRHa group a
129 brain abscess patients (37% females) with a
median follow-up time of 5.9 years (interquartile range
130 brain abscess patients (37% females) with a
median follow-up time of 5.9 years (IQR 1.1-14.2).
131 a median age of 62 years (range 17-86) and a
median follow-up time of 53 months (range 1-204).
132 After a
median follow-up time of 53 months, the actuarial median
133 or PCO was obtained from 270 patients with a
median follow-up time of 57 months (range 50-64 months).
134 During the
median follow-up time of 57 months, 350 children develop
135 le range, 35 to 58 years) at diagnosis and a
median follow-up time of 58 months (interquartile range,
136 With a
median follow-up time of 58 months, PFS at 5 years was 6
137 matory drug (NSAID) users (n = 315).During a
median follow-up time of 59 mo, 200 participants (43.8%)
138 With a
median follow-up time of 59 months for 2,181 patients st
139 During a
median follow-up time of 59 months, 214 RFS events occur
140 During a
median follow-up time of 6 (25th-75th, 4-10) years, 22 p
141 r) and 200 breast cancer recurrences after a
median follow-up time of 6.0 y after the 2009 re-intervi
142 With a
median follow-up time of 6.3 months, the quality of life
143 At a
median follow-up time of 6.3 years, there were no statis
144 The study was closed after a
median follow-up time of 60 months, with a relapse rate
145 During a
median follow-up time of 62.5 months, 564 of the 3,478 p
146 complete response after transplantation at a
median follow-up time of 67 months.
147 of NODM was 26.4% in liver recipients with a
median follow-up time of 685 days.
148 With a
median follow-up time of 69 months (range, 6-112 months;
149 After a
median follow-up time of 696 days (interquartile range 1
150 After a
median follow-up time of 696 days (interquartile range 1
151 Over a
median follow-up time of 7 years, 74 of 103 treated pati
152 Results With a
median follow-up time of 7.4 years, 25 (11.6%) of 216 pa
153 After a
median follow-up time of 7.6 years, the previously descr
154 a diagnosis of CD from 2008 to 2017, with a
median follow-up time of 7.8 years.
155 were more likely to remain carriers after a
median follow-up time of 70 days than women not using su
156 Participants had a
median follow-up time of 720 days.
157 herapy, and no metastases were recorded in a
median follow-up time of 73.2 months (mean, 71.5; range,
158 With a
median follow-up time of 73.9 months (interquartile rang
159 During a
median follow-up time of 74.0 months, there were 327 kid
160 At a
median follow-up time of 79.5 months for all surviving p
161 At a
median follow-up time of 8 years, 465 patients had died,
162 During a
median follow-up time of 8 years, 631 (6.8%) patients de
163 After a
median follow-up time of 8.3 years (range, 0-26 years),
164 th HF with preserved ejection fraction and a
median follow-up time of 8.6 years.
165 After a
median follow-up time of 8.7 y, prostate cancer was diag
166 (n = 1,215) and replacement (n = 467) for a
median follow-up time of 8.7 years.
167 After a
median follow-up time of 84 months, event-free and overa
168 Over a
median follow-up time of 9.1 years (interquartile range,
169 During the
median follow-up time of 9.5 years, mortality was 24.2%
170 ity was observed in 40% of patients during a
median follow-up time of 9.7 years.
171 With a
median follow-up time of 964 days (range, 569 to 1,162 d
172 still experienced wheat sensitivity after a
median follow-up time of 99 months.
173 At a
median follow-up time of about 5 years, 61 participants
174 Over a
median follow-up time of approximately 4 years, after ad
175 The
median follow-up time of living patients was 124.5 month
176 ponse was not reached in either cohort, with
median follow-up times of 12.8 months (IQR 9.3-15.5) in
177 dence, 1.3%) in the primary OAC group during
median follow-up times of 42.6 months (range, 6.2-97.1 m
178 With
median follow-up times of 86 months in the DA-EPOCH-R gr
179 With a
median follow-up time since allo-HSCT of 16 years (range
180 With 60-month
median follow-up time,
the overall RR for 121 assessable
181 The
median follow-up time to assess platelet responses was 1
182 The
median follow-up time to death or last survey since ALL
183 Median follow-up time to first SMN diagnosis was 26.3 ye
184 Median follow up time was 24 months.
185 For diabetes assessment, the
median follow-up time was 10 years (interquartile range
186 Median follow-up time was 10.8 years (range, 0 to 16.9 y
187 Median follow-up time was 10.9 years.
188 The
median follow-up time was 12 months (5 days-7 years), bu
189 Median follow-up time was 12.3 years.
190 Median follow-up time was 12.6 (to a maximum of 28.2) ye
191 The
median follow-up time was 136 months.
192 The
median follow-up time was 14.5 months.
193 Median follow-up time was 14.9 months (range, 0.4 to 36.
194 Median follow-up time was 1467 days (IQR 1029-2052) and
195 Median follow-up time was 15 (1-32) months.
196 The
median follow-up time was 15.5 y.
197 The
median follow-up time was 15.8 years.
198 Median follow-up time was 155 days (IQR 77-357) in the p
199 Median follow-up time was 16.8 months (range, 3.4-84.8 m
200 The
median follow-up time was 160 days.
201 Median follow-up time was 17 months (range, 7 to 30 mont
202 Median follow-up time was 17 months.
203 For diabetes complications, the
median follow-up time was 17.6 years (IQR, 14.2-19.8) an
204 Median follow-up time was 2.0 years (IQR 1.9-3.0).
205 Median follow-up time was 2.4 (0.9-4.0) years.
206 The
median follow-up time was 2.5 years.
207 Median follow-up time was 2.6 (0.8-4.5) years.
208 The
median follow-up time was 2.7 years.
209 Median follow-up time was 2.9 years.
210 Median follow-up time was 20.0 months (IQR 15.0-25.6) in
211 As of the cutoff date of Dec 29, 2017,
median follow-up time was 21.5 months (IQR 16.7-24.3) fo
212 The
median follow-up time was 23 months (interquartile range
213 Median follow-up time was 23.1 months.
214 Median follow-up time was 24 (range, 3-112) weeks.
215 Median follow-up time was 24 months (IQR 20-25) in the n
216 ce interval (CI): 19.8-22.5 months], whereas
median follow-up time was 25.1 months (95% CI: 23.5-26.5
217 Median follow-up time was 26.3 months (range, 2.0-47.2 m
218 Median follow-up time was 28 (interquartile range 19-41)
219 Median follow-up time was 28.2 months (range, 4-38 month
220 The
median follow-up time was 29.0 months.
221 For 518 patients, the
median follow-up time was 29.3 months (range, 1 to 149 m
222 Median follow-up time was 29.7 months (95% confidence in
223 Median age was 51.1 years, and
median follow-up time was 3 years.
224 The
median follow-up time was 3.0 years.
225 The
median follow-up time was 3.1 years.
226 The
median follow-up time was 3.3 years.
227 The
median follow-up time was 3.5 years for the ATG group an
228 Median follow-up time was 3.6 (IQR: 1.5-6.4) years.
229 Median follow-up time was 3.6 (IQR:1.5-6.4) years.
230 The
median follow-up time was 30 months (range, 1-109).
231 The
median follow-up time was 34 months (range, 1-297).
232 The
median follow-up time was 35 mo (range, 7-39 mo).
233 Median follow-up time was 35 months (IQR 14-56), with a
234 Median follow-up time was 36 months (IQR 30-46) in the p
235 The
median follow-up time was 37 months [95%CI 35;39].
236 The
median follow-up time was 38 months (95% confidence inte
237 The
median follow-up time was 4 years.
238 Median follow-up time was 4 years.
239 Median follow-up time was 4.0 years (0.3-8.9).
240 The
median follow-up time was 4.01 years.
241 Median follow-up time was 4.38 years (range, 0.04 to 5.5
242 The
median follow-up time was 4.5 years (range, 6 weeks-25 y
243 Of the 911 recipients, the
median follow-up time was 4.7 years resulting in 4825 pe
244 The
median follow-up time was 4.8 years.
245 Median follow-up time was 4.9 months (range, 0-12 months
246 The
median follow-up time was 44 months.
247 The
median follow-up time was 47 months (range, 13 to 80 mon
248 Median follow-up time was 5 years (range, 0.6 to 12.7 ye
249 The
median follow-up time was 5 years with a total of 703 vi
250 The
median follow-up time was 5.0 years (interquartile range
251 The
median follow-up time was 5.0 years, and the proportions
252 on natalizumab was 3.3 (range 0-11.6) years;
median follow-up time was 5.2 (range 0-10.8) years.
253 Median follow-up time was 5.2 months (range, 1-11).
254 Median follow-up time was 5.4 years (3 months to 12.5 ye
255 Median follow-up time was 5.4 years (interquartile range
256 The
median follow-up time was 5.6 mo (range, 3.7-23.2 mo).
257 The
median follow-up time was 50 months (range, 2-142 months
258 The
median follow-up time was 52 months (range, 13-118 month
259 The
median follow-up time was 54.3 months (95% CI, 48.4 to 6
260 Median follow-up time was 59 months for patients still a
261 Median follow-up time was 6.1 years.
262 Median follow-up time was 6.4 years.
263 The
median follow-up time was 6.4 years.
264 The
median follow-up time was 6.6 years.
265 Median follow-up time was 6.7 months (IQR 4.4-10.2), wit
266 Median follow-up time was 6.7 years from the time of dia
267 Median follow-up time was 6.7 years per recipient; total
268 Eighty-two patients underwent surgery; the
median follow-up time was 6.8 and 6.4 years, respectivel
269 Median follow-up time was 60 days for patients with comm
270 The
median follow-up time was 60 months (interquartile range
271 The
median follow-up time was 60 months (range, 1-158 months
272 Median follow-up time was 7 years (range: 0-13 years) wi
273 The
median follow-up time was 7.1 years.
274 Median follow-up time was 7.17 years (range, 0.01 to 11.
275 The
median follow-up time was 7.2 years (range, 0.7-18 years
276 The
median follow-up time was 7.4 months, with an interquart
277 The
median follow-up time was 7.4 years (quartiles, 4.6-10.3
278 Median follow-up time was 7.5 years.
279 The
median follow-up time was 7.6 years (range, 0.1 to 10.1
280 The
median follow-up time was 7.7 mo (range, 0.4-50.1 mo).
281 Median follow-up time was 7.7 years.
282 Median follow-up time was 7.9 years.
283 For the total of patients, the
median follow-up time was 70.3 months.
284 Median follow-up time was 71 months.
285 The
median follow-up time was 8.1 years.
286 The
median follow-up time was 8.4 years.
287 Median follow-up time was 81.1 months.
288 The
median follow-up time was 82 months (range, 6-329 months
289 Median follow-up time was 83 months and 58 months for UC
290 The
median follow-up time was 9 years (range, 2.9 to 16.8 ye
291 The
median follow-up time was 9.8 y.
292 Median follow-up time was 91 months (range 17-333 months
293 The
median follow-up time was 922 days.
294 Median follow-up time was 98.0 months (range: 3.0-1095.0
295 Results
Median follow-up times were 15.0, 21.7, and 14.6 months
296 Mean and
median follow-up times were 2.6 (SD, 1.5) and 2.5 (inter
297 After propensity matching, the respective
median follow-up times were 3.72 years and 3.76 years.
298 For the rofecoxib and placebo arms,
median follow-up times were 4.84 and 4.85 years, with 24
299 Median follow-up times were 6.1 years and 9.0 years for
300 pants with cardiovascular disease; 4.9 years
median follow-up time)
with fasting lipids, apolipoprote